Barbara Domayne-Hayman

Barbara has 30 years’ experience in the life sciences industry, with the first 11 years on the commercial side of a large organisation (ICI/Zeneca/AstraZeneca), after which she transitioned to the entrepreneurial world of biotech and emerging companies.

She has worked in a wide range of biotechs, including both therapeutic product and platform technology companies, working in business development, as CEO and in non-exec roles including Chair.

Barbara has been involved in a number of major strategic transactions and fundraising, but her main focus is on helping to build companies. She is Chief Business Officer of Autifony Therapeutics. Barbara is also on the Cambridge Enterprise Seed Investment Committee and chairs the LifeArc Seed Investment Committee.